Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 14
- Registration Number
- NCT00521781
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
- Conditions
- Interventions
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 413
- Registration Number
- NCT00514917
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00512668
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT00486642
- Locations
- 🇨🇦
Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada
🇨🇦London Regional Cancer Program, London, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 9
- Registration Number
- NCT00482807
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 127
- Registration Number
- NCT00470834
- Locations
- 🇨🇦
GSK Investigational Site, Quebec, Canada
Bicalutamide in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00468715
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸Ralph Lauren Center for Cancer Care and Prevention, New York, New York, United States
Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
- Conditions
- First Posted Date
- 2007-01-12
- Last Posted Date
- 2007-10-08
- Lead Sponsor
- University of L'Aquila
- Target Recruit Count
- 119
- Registration Number
- NCT00421694
- Locations
- 🇮🇹
University of L'Aquila, L'Aquila, Abruzzo, Italy
Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy
- Conditions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2007-10-08
- Lead Sponsor
- University of L'Aquila
- Target Recruit Count
- 86
- Registration Number
- NCT00418080
- Locations
- 🇮🇹
University of L'Aquila, L'Aquila, Abruzzo, Italy
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00388804
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.